Neurogene vs Rocket Pharmaceuticals
NGNE and RCKT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NGNE and RCKT compare
Neurogene is the larger company, worth 2.0 times as much as Rocket Pharmaceuticals ($462M against $232M).
Neurogene scores higher on the StockData Score (7 against 3 for Rocket Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NGNE | RCKT |
|---|---|---|
| Size and price | ||
| Market cap | $462M | $232M |
| Share price | $23.10 | $2.11 |
| Change, 1 year | 1.4% | −30.8% |
| Change, 5 years | −77.4% | −91.1% |
| Beta (5Y) | 2.01 | 2.32 |
| Employees | 131 | 202 |
| StockData Score | ||
| Total score | 7 (better) | 3 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 2.1× | 0.6× (better) |
| FCF yield | −19.0% (better) | −73.6% |
| Profitability | ||
| Return on equity | −45.3% | −4.8% (better) |
| Return on invested capital | – | −180% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −60673.0× | −101.3× (better) |
| Current ratio | 10.64 (better) | 9.24 |
| Altman Z-score | 7.17 (better) | −2.72 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 86.5% | 90.9% |
| Held by insiders | 15.9% | 22.3% |
| Insider net buying, 12 months | −$1.1M | −$934K (better) |
| Short interest, % of float | 33.8% | 19.0% |
Go deeper
- NGNE stock overview
- NGNE income statement
- NGNE valuation and score
- RCKT stock overview
- RCKT income statement
- RCKT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.